What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Heart failure
- Cardiology
His primary areas of study are Heart failure, Internal medicine, Cardiology, Heart disease and Ejection fraction.
His Heart failure study combines topics in areas such as Randomized controlled trial, Hazard ratio, Confidence interval, Intensive care medicine and Placebo.
His Internal medicine study deals with Surgery intersecting with Renal function and Relative risk.
Christopher M. O'Connor combines subjects such as Clinical endpoint and Blood pressure with his study of Cardiology.
His studies deal with areas such as Clinical trial, Randomization, Mortality rate, Emergency medicine and Survival analysis as well as Heart disease.
His Ejection fraction research integrates issues from Cardiomyopathy and Depression.
His most cited work include:
- Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. (1382 citations)
- Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. (1354 citations)
- Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina (1147 citations)
What are the main themes of his work throughout his whole career to date?
Christopher M. O'Connor mainly investigates Heart failure, Internal medicine, Cardiology, Intensive care medicine and Ejection fraction.
His Heart failure research is multidisciplinary, incorporating elements of Clinical trial, Randomized controlled trial, Heart disease and Hazard ratio.
His studies in Internal medicine integrate themes in fields like Placebo and Surgery.
His work carried out in the field of Cardiology brings together such families of science as Blood pressure and Renal function.
His Intensive care medicine study incorporates themes from Diuretic, MEDLINE and Emergency medicine.
His Ejection fraction research includes elements of Natriuretic peptide and Physical therapy.
He most often published in these fields:
- Heart failure (74.83%)
- Internal medicine (69.25%)
- Cardiology (55.92%)
What were the highlights of his more recent work (between 2015-2021)?
- Heart failure (74.83%)
- Internal medicine (69.25%)
- Cardiology (55.92%)
In recent papers he was focusing on the following fields of study:
Christopher M. O'Connor mostly deals with Heart failure, Internal medicine, Cardiology, Ejection fraction and Clinical trial.
His study in Heart failure is interdisciplinary in nature, drawing from both Placebo, Randomized controlled trial, Confidence interval and Intensive care medicine.
His Intensive care medicine study combines topics from a wide range of disciplines, such as MEDLINE and Quality of life.
His Hazard ratio, Nesiritide, Renal function and Proportional hazards model study, which is part of a larger body of work in Internal medicine, is frequently linked to Rolofylline, bridging the gap between disciplines.
His is doing research in Natriuretic peptide, Acute decompensated heart failure, Myocardial infarction, Coronary artery disease and Cardiogenic shock, both of which are found in Cardiology.
His Ejection fraction research includes themes of Blood pressure, Clinical endpoint, Quality of life and Physical therapy.
Between 2015 and 2021, his most popular works were:
- Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. (219 citations)
- Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial (198 citations)
- Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (176 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Heart failure
- Cardiology
His main research concerns Heart failure, Internal medicine, Cardiology, Ejection fraction and Hazard ratio.
His Heart failure study integrates concerns from other disciplines, such as Clinical trial, Quality of life, Randomized controlled trial, Confidence interval and Intensive care medicine.
Within one scientific family, Christopher M. O'Connor focuses on topics pertaining to Placebo under Internal medicine, and may sometimes address concerns connected to Pulmonary hypertension.
His work deals with themes such as Biomarker and Diuretic, which intersect with Cardiology.
Christopher M. O'Connor has researched Ejection fraction in several fields, including Physical therapy, Proportional hazards model, Clinical endpoint and Heart rate.
His Hazard ratio research incorporates elements of Implantable cardioverter-defibrillator and Brain natriuretic peptide.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
